Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioporto ASTHOXF 68 Net Cash per Share is $0.01 as of Jun. 2026. GuruFocus rates THOXF with a GF Score™ of 68/100 and a GF Value™ of $0.14. The stock has 5 warning signs investors should review. Among 59 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 64.41% on this metric.
The historical rank and industry rank for Bioporto AS's Net Cash per Share or its related term are showing as below:
THOXF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.87 Med: 19.92 Max: 258.09
Current: 14.9
During the past 13 years, the highest Price-to-Net-Cash Ratio of Bioporto AS was 258.09. The lowest was 5.87. And the median was 19.92.
THOXF's Price-to-Net-Cash is ranked worse than 64.41% of 59
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.6
vs THOXF: 14.90
Bioporto AS (OTCPK:THOXF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Bioporto AS Net Cash per Share Related Terms
Bioporto AS Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THOXF vs TMO, DHR, IDXX: Net Cash per Share Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Price-to-Net-Cash vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Bioporto AS's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a Net Cash per Share of $0.01 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #38 out of 59 companies in the Medical Diagnostics & Research industry, placing it in the top 64.4%.
Is Bioporto AS's Net Cash per Share too high?
Bioporto AS's current Net Cash per Share is $0.01. The Medical Diagnostics & Research industry median Net Cash per Share is 9.60. Bioporto AS's value of $0.01 is 99.9% below this industry median. Based on the distribution chart, Bioporto AS ranks #38 out of 59 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bioporto AS has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Net Cash per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #38 out of 59 companies for Net Cash per Share. This places Bioporto AS in the lower half of its industry. The industry median Net Cash per Share is 9.60. Bioporto AS's value of $0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Diagnostics & Research company?
The median Net Cash per Share among Medical Diagnostics & Research companies is 9.60, based on 59 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Net Cash per Share of $0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Net Cash per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Net Cash per Share is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Net Cash per Share of $0.01. The stock's GF Value™ is $0.14, compared to a current price of $0.15 — trading 6.4% above its estimated fair value. The current Net Cash per Share is $0.01 and 99.9% below the Medical Diagnostics & Research industry median of 9.60. Bioporto AS's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Net Cash per Share is $0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be overvalued.
The current stock price of $0.15 is trading 6.4% above its estimated GF Value™ of $0.14.
Key valuation signals for THOXF:
Net Cash per Share: $0.01
GF Value™: $0.14 vs. price of $0.15 (6.4% above fair value)
Industry Position: 99.9% below the Medical Diagnostics & Research median (#38 of 59)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
68GF Score
Get the complete analysis for THOXF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
